Copyright © 2001 by the European Society of Cardiology.
Editorials
Cholesterol reduction: What can we afford?
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota, U.S.A.
References
- van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors: whom to treat? Eur Heart J. 2001;22:751761
[Abstract/Free Full Text] - Lancet. 1994;344:13831389[CrossRef][ISI][Medline]
- Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:10011009
[Abstract/Free Full Text] - Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:13011307
[Abstract/Free Full Text] - Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:16151622
[Abstract/Free Full Text] - N Engl J Med. 1998;339:13491357
[Abstract/Free Full Text] - Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Eur Heart J. 1996;17:10011007
[Abstract/Free Full Text] - Ashraf T, Hay JW, Pitt B. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409414[CrossRef][ISI][Medline]
- Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332336
[Abstract/Free Full Text] - Caro J, Klittich W, McGuire A. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315:15771582
[Abstract/Free Full Text] - McGovern PG, Arnett DK, Shahar E, Luepker RV. Trends in serum cholesterol levels, 19801997: The Minnesota Heart Survey. Circulation. 1999;99:1104
[Free Full Text] - http://bernie.house.gov/legislation/pharmbill/drugsheet.asp
- Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study group. N Engl J Med. 1999;341:410418
[Abstract/Free Full Text] - Keys A. Seven Countries: A multivariate analysis of death and coronary heart disease. Cambridge: Harvard University Press; 1980.
- Cleeman JI, Lenfant C. The National Cholesterol Education Program: Progress and Prospects. JAMA. 1998;280:20992104
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||